AIMS: Low rifampicin plasma concentrations can lead to treatment failure and increased risk of developing drug resistant tuberculosis. The objectives of this study were to characterize the population pharmacokinetics (popPK) of rifampicin in Malawian children and adults with tuberculosis, simulate exposures under revised WHO dosing guidelines that aim to reduce the risk of low exposures of rifampicin and examine predicted exposures using weight- and age-based dosing bands under new dosing recommendations. METHODS: Patients were recruited at least two weeks after initiation of the intensive phase of treatment and received RIF in FDC of anti-TB drugs. A total of 5-6 rich and 1-2 sparse samples were collected. nonmem (v7.2) was used to build a population-PK model. RESULTS: A 165 TB patients, 115 adults and 50 children, aged 7 months to 65 years and weighing 4.8 to 87 kg, were included in the one compartment model with first order absorption best described the data. The mean population estimate for CL/F was 23.9 (l h(-1) 70 kg(-1) ) with inter-individual variability of 46.6%. Exposure was unaffected by HIV status. Relative bioavailability in children was estimated at 49% lower compared to adults (100% relative bioavailability). Simulations showed significantly lower rifampicin exposure in children vs. adults. In children average AUC was 13.5 mg l(-1) h, which was nearly half that was observed in adults (26.3 mg l(-1) h). Using age as a surrogate for weight in dosing bands gave similar results compared with the weight bands. Increasing dose to approximately 15 mg kg(-1) , increased AUC in children to an average of 22 mgl(-1) h. bringing expected exposures in children closer to those predicted for adults. CONCLUSION: The popPK model developed can be used to optimize rifampicin exposures through dosing simulations. WHO dosing recommendations may not be achieved using currently licensed fixed dose combination formulations of TB therapy.
AIMS: Low rifampicin plasma concentrations can lead to treatment failure and increased risk of developing drug resistant tuberculosis. The objectives of this study were to characterize the population pharmacokinetics (popPK) of rifampicin in Malawian children and adults with tuberculosis, simulate exposures under revised WHO dosing guidelines that aim to reduce the risk of low exposures of rifampicin and examine predicted exposures using weight- and age-based dosing bands under new dosing recommendations. METHODS: Patients were recruited at least two weeks after initiation of the intensive phase of treatment and received RIF in FDC of anti-TB drugs. A total of 5-6 rich and 1-2 sparse samples were collected. nonmem (v7.2) was used to build a population-PK model. RESULTS: A 165 TB patients, 115 adults and 50 children, aged 7 months to 65 years and weighing 4.8 to 87 kg, were included in the one compartment model with first order absorption best described the data. The mean population estimate for CL/F was 23.9 (l h(-1) 70 kg(-1) ) with inter-individual variability of 46.6%. Exposure was unaffected by HIV status. Relative bioavailability in children was estimated at 49% lower compared to adults (100% relative bioavailability). Simulations showed significantly lower rifampicin exposure in children vs. adults. In children average AUC was 13.5 mg l(-1) h, which was nearly half that was observed in adults (26.3 mg l(-1) h). Using age as a surrogate for weight in dosing bands gave similar results compared with the weight bands. Increasing dose to approximately 15 mg kg(-1) , increased AUC in children to an average of 22 mgl(-1) h. bringing expected exposures in children closer to those predicted for adults. CONCLUSION: The popPK model developed can be used to optimize rifampicin exposures through dosing simulations. WHO dosing recommendations may not be achieved using currently licensed fixed dose combination formulations of TB therapy.
Authors: Michael J Blake; Susan M Abdel-Rahman; Richard F Jacobs; Nancy K Lowery; Timothy R Sterling; Gregory L Kearns Journal: Pediatr Infect Dis J Date: 2006-05 Impact factor: 2.129
Authors: Jotam G Pasipanodya; Helen McIlleron; André Burger; Peter A Wash; Peter Smith; Tawanda Gumbo Journal: J Infect Dis Date: 2013-07-29 Impact factor: 5.226
Authors: Simbarashe P Zvada; Paolo Denti; Peter R Donald; H Simon Schaaf; Stephanie Thee; James A Seddon; Heiner I Seifart; Peter J Smith; Helen M McIlleron; Ulrika S H Simonsson Journal: J Antimicrob Chemother Date: 2014-01-31 Impact factor: 5.790
Authors: Jordan W Tappero; Williamson Z Bradford; Tracy B Agerton; Philip Hopewell; Arthur L Reingold; Shahin Lockman; Aderonke Oyewo; Elizabeth A Talbot; Thomas A Kenyon; Themba L Moeti; Howard J Moffat; Charles A Peloquin Journal: Clin Infect Dis Date: 2005-07-08 Impact factor: 9.079
Authors: Marc Weiner; Charles Peloquin; William Burman; Chi-Cheng Luo; Melissa Engle; Thomas J Prihoda; William R Mac Kenzie; Erin Bliven-Sizemore; John L Johnson; Andrew Vernon Journal: Antimicrob Agents Chemother Date: 2010-07-26 Impact factor: 5.191
Authors: Hendrik Simon Schaaf; Marianne Willemse; Karien Cilliers; Demetre Labadarios; Johannes Stephanus Maritz; Gregory D Hussey; Helen McIlleron; Peter Smith; Peter Roderick Donald Journal: BMC Med Date: 2009-04-22 Impact factor: 8.775
Authors: Stijn W van Beek; Rob Ter Heine; Ron J Keizer; Cecile Magis-Escurra; Rob E Aarnoutse; Elin M Svensson Journal: Clin Pharmacokinet Date: 2019-06 Impact factor: 6.447
Authors: Roger K Verbeeck; Gunar Günther; Dan Kibuule; Christian Hunter; Tim W Rennie Journal: Eur J Clin Pharmacol Date: 2016-06-15 Impact factor: 2.953
Authors: Robin J Svensson; Katarina Niward; Lina Davies Forsman; Judith Bruchfeld; Jakob Paues; Erik Eliasson; Thomas Schön; Ulrika S H Simonsson Journal: Br J Clin Pharmacol Date: 2019-07-25 Impact factor: 4.335
Authors: Anthony J Garcia-Prats; Elin M Svensson; Jana Winckler; Heather R Draper; Lee Fairlie; Louvina E van der Laan; Masebole Masenya; H Simon Schaaf; Lubbe Wiesner; Jennifer Norman; Rob E Aarnoutse; Mats O Karlsson; Paolo Denti; Anneke C Hesseling Journal: J Antimicrob Chemother Date: 2021-11-12 Impact factor: 5.758
Authors: Robin J Svensson; Rob E Aarnoutse; Andreas H Diacon; Rodney Dawson; Stephen H Gillespie; Martin J Boeree; Ulrika S H Simonsson Journal: Clin Pharmacol Ther Date: 2017-08-07 Impact factor: 6.875
Authors: K E Stott; H Pertinez; M G G Sturkenboom; M J Boeree; R Aarnoutse; G Ramachandran; A Requena-Méndez; C Peloquin; C F N Koegelenberg; J W C Alffenaar; R Ruslami; A Tostmann; S Swaminathan; H McIlleron; G Davies Journal: J Antimicrob Chemother Date: 2018-09-01 Impact factor: 5.790
Authors: Marieke G G Sturkenboom; Anne-Grete Märtson; Elin M Svensson; Derek J Sloan; Kelly E Dooley; Simone H J van den Elsen; Paolo Denti; Charles A Peloquin; Rob E Aarnoutse; Jan-Willem C Alffenaar Journal: Clin Pharmacokinet Date: 2021-03-06 Impact factor: 6.447